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Hereditary hemochromatosis, an iron overload dis-
ease caused by a deficiency in the iron-regulatory
hormone hepcidin, is associated with lethal infec-
tions by siderophilic bacteria. To elucidate themech-
anisms of this susceptibility, we infected wild-type
and hepcidin-deficient mice with the siderophilic
bacterium Vibrio vulnificus and found that hepcidin
deficiency results in increased bacteremia and
decreased survival of infected mice, which can be
partially ameliorated by dietary iron depletion. Addi-
tionally, timely administration of hepcidin agonists to
hepcidin-deficient mice induces hypoferremia that
decreases bacterial loads and rescues these mice
from death, regardless of initial iron levels. Studies
of Vibrio vulnificus growth ex vivo show that high
iron sera from hepcidin-deficient mice support
extraordinarily rapid bacterial growth and that this
is inhibited in hypoferremic sera. Our findings
demonstrate that hepcidin-mediated hypoferremia
is a host defense mechanism against siderophilic
pathogens and suggest that hepcidin agonists may
improve infection outcomes in patients with heredi-
tary hemochromatosis or thalassemia.
INTRODUCTION
Iron, required as a cofactor for many important biological pro-
cesses, is an essential nutrient for nearly all living organisms.
The requirement for this metal places it in a critical role at the
host-pathogen interface: microbes evolved complex means to
acquire iron from the host (Marx, 2002; Schaible and Kaufmann,
2004), and the host evolved the ability to resist infection by
sequestering iron so it is less available to microbes.
Hereditary hemochromatosis, a common genetic iron over-
load disease (Ganz and Nemeth, 2011), increases susceptibil-
ity to infections with Vibrio vulnificus and Yersinia enterocoli-Cell Htica (Khan et al., 2007), Gram-negative bacteria classified as
‘‘siderophilic’’ because their pathogenicity is enhanced by
excess iron (Weinberg, 2008, 2009). Vibrio vulnificus causes
fulminant sepsis with mortality higher than 50% in susceptible
patients, including those with hereditary hemochromatosis and
other iron overload conditions (Horseman and Surani, 2011),
but it does not cause severe illness in healthy individuals.
It is not known which specific manifestations of hereditary
hemochromatosis predispose to infection with siderophilic mi-
crobes: liver injury, tissue iron loading, high baseline plasma
iron concentrations, or the inability to lower iron concentra-
tions in plasma in response to infections.
Hereditary hemochromatosis is caused by deficiency of the
iron-regulatory hormone hepcidin (Ganz and Nemeth, 2011).
Hepcidin is a 25 amino acid peptide secreted by hepatocytes.
It controls iron concentrations in extracellular fluid and blood
plasma by regulating the amount of ferroportin, the sole known
cellular iron exporter. Ferroportin transports absorbed, re-
cycled, or stored iron from tissues into plasma (Donovan
et al., 2005). Hepcidin binding to ferroportin triggers its degra-
dation, resulting in decreased transfer of iron to plasma and,
consequently, hypoferremia (Nemeth et al., 2004b). During in-
fections or in response to injection of microbial molecules,
hepcidin production is greatly enhanced (Armitage et al.,
2011; Rodriguez et al., 2014), stimulated by inflammatory cyto-
kines including interleukin-6 (IL-6) (Nemeth et al., 2004a; Ro-
driguez et al., 2014), and possibly activin B (Besson-Fournier
et al., 2012). It has been proposed that hepcidin-mediated hy-
poferremia functions as a host defense mechanism that
evolved to restrict iron availability for pathogen growth (Drake-
smith and Prentice, 2012; Ganz, 2009), but this has never been
demonstrated. Hepcidin was also reported to have direct
bactericidal activity in vitro (Krause et al., 2000; Park et al.,
2001), but the effect is seen only at unphysiologically high
concentrations.
Here we demonstrate that hepcidin has a critical role in host
defense against V. vulnificus by inducing reactive hypoferremia
during early phases of infection. In addition, we show that
acute pre- or postexposure treatment of susceptible mice with
hepcidin agonists mitigates the high mortality caused by this
pathogen.ost & Microbe 17, 47–57, January 14, 2015 ª2015 Elsevier Inc. 47
Figure 1. Vibrio vulnificus Infection Is Highly
Lethal in Hepcidin-Deficient Mice
(A and B) Kaplan-Meier survival curves for iron-
depleted (A) and iron-loaded (B) mice after infec-
tion with 103 (dashed lines) or 105 (solid lines) CFU
of V. vulnificus (n = 4–11 in each group). WT and
Hamp1/ mice were iron depleted or iron loaded
by dietary modification (WT: 4 ppm or 10,000 ppm
Fe diet for 2 weeks; Hamp1/: 4 ppm or standard
diet for 4–6 weeks; see Experimental Procedures).
By multifactorial Kaplan-Meier log-rank analysis,
differences in survival betweenWT and Hamp1/
mice were significant in both iron-depleted (com-
bined CFU, p < 0.05) and iron-loaded conditions
(combined CFU, p < 0.001).
(C) Liver iron stores weremeasured in a parallel set
of mice and confirmed the effective modulation of
iron stores by dietary iron manipulation (n = 5–10
per group). For liver iron measurements, statistical
significance was assessed using Student’s t test if
data were normally distributed (**p < 0.01) or
Mann-Whitney U test if they were not normally
distributed (++p < 0.01). See also Figure S1.RESULTS
Hepcidin Is Required for Resistance to V. vulnificus
Infection
Iron is thought to be required for rapid growth of V. vulnificus
and lethality during infections, as was previously demonstrated
in mice injected with iron dextran (Starks et al., 2000; Wright
et al., 1981). To examine whether the iron-regulatory hormone
hepcidin affects the response to infection, we compared the
severity of the V. vulnificus infection in wild-type (WT) and hep-
cidin knockout (Hamp1/) mice. Mice were iron depleted or
iron loaded by dietary manipulations and infected subcutane-
ously (s.c.) with a low (103 colony-forming units [CFU]) or mod-
erate (105 CFU) inoculum of V. vulnificus. In both iron-depleted
(Figure 1A) and iron-loaded (Figure 1B) conditions, Hamp1/
mice were significantly more susceptible than WT mice: iron-
loaded Hamp1/ died within 1 day after infection and iron-
depleted Hamp1/ within the next several days, whereas
WT mice survived the infection. WT mice were susceptible
to V. vulnificus infection only when iron loaded (Table S1, avail-
able online) and infected with a large inoculum of V. vulnificus
(106 CFU). Under those conditions, iron-loaded mice died
within 2 days after infection, while most of the iron-depleted
mice still survived (Figure S1A), confirming that iron has a strik-
ing effect on V. vulnificus lethality. The differential susceptibility
of WT and Hamp1/ to V. vulnificus infection was not attribut-
able to their baseline liver iron differences because iron-
depleted Hamp1/ mice were much more susceptible to48 Cell Host & Microbe 17, 47–57, January 14, 2015 ª2015 Elsevier Inc.infection even though they had lower
liver iron stores than iron-loaded WT
mice, as measured in a parallel set
of mice maintained under the same
conditions as the mice used for the
survival experiments (Figure 1C). As
V. vulnificus is an extracellular pathogen
(Gulig et al., 2005), intracellular hepato-cyte iron is not likely to play a direct role in the growth of these
bacteria.
To examine whether extracellular iron concentrations alter the
growth rate of V. vulnificus, we assessed bacterial growth ex vivo
in sera collected from uninfected iron-loaded or iron-depleted
WT animals. V. vulnificus growth was greatly enhanced in serum
derived from iron-loaded compared to iron-depleted mice (Fig-
ure S1B). Supplementing iron-depleted serum with ferric ammo-
nium citrate (FAC) also enhanced bacterial growth. Conversely,
addition of the synthetic iron chelator deferiprone to iron-rich
serum prevented bacterial growth. Interestingly, growth in low-
iron serum was similar to the growth under standard conditions
in LB-N broth. This indicates that V. vulnificus can grow
adequately even with limited iron availability, but excess iron
greatly increases the growth rate. In iron-rich serum, bacteria un-
derwent 18 divisions within 3 hr, or one division every 10 min,
an astoundingly rapid growth rate.
Human infections with V. vulnificus and their laboratory
models often terminate in septic shock (Shan et al., 2012). To
verify that this mechanism contributed to rapid death of iron-
loadedmice, we inspected hematoxylin and eosin (H&E)-stained
skin (site of injection) and liver sections of Hamp1/ mice
injected with 103 CFU of V. vulnificus or saline. The venules in
the skin and hepatic circulation of infected mice were greatly
dilated compared with saline-treated mice (Figures 2A–2D and
2E–2H). The vasodilatation was accompanied by erythrocyte
sludging characteristic of circulatory shock. In the skin, massive
aggregates of bacteria were visible in the perivascular space
Figure 2. Local V. vulnificus Proliferation Induces Vasodilation,
Leukostasis, and Erythrocyte Sludging
(A–H) Photomicrographs of skin sections at the site of injection are shown.
Saline-injected mice and mice injected with 103 CFU of V. vulnificus were
analyzed in pairs when V. vulnificus-injected mice became moribund: (A) H&E
stain, saline injection; (B) H&E stain, V. vulnificus injection, note dilated venules
(v) and arterioles (a), leukostasis, and erythrocyte sludging; (C) 403 magnifi-
cation detail of (A); (D) 403 magnification detail of (B); (E) Gram stain and
tartrazine, saline injection, section adjacent to (C); (F) Gram stain and tar-
trazine, V. vulnificus injection, section adjacent to (D); (G) 1003 magnification
detail of (E); (H) 1003magnification detail of (F), note numerous purple-staining
bacteria (arrow) in perivascular spaces of V. vulnificus-infected mice. See also
Figure S2.(Figures 2E–2H). In the liver, no bacteria were seen, but therewas
neutrophilic infiltration in perivenular spaces (Figure S2). These
findings are consistent with endotoxemic shock.
To determine whether the susceptibility of Hamp1/ mice to
severe V. vulnificus infection was due to greater bacteremia and
bacterial dissemination, we assayed bacterial CFU counts in
blood and liver of iron-depleted and iron-loaded WT and
Hamp1/ mice 16 hr after infection. Liver CFU counts likely
represent extracellular bacteria, as V. vulnificus does not appear
to invade cells (Gulig et al., 2005). To allow Hamp1/ mice to
survive long enough to undergo analysis at the 16 hr time point,
we injected all groups with a small inoculum of bacteria (300Cell HCFU). After infection with this low dose, only iron-loaded
Hamp1/ mice, but not iron-depleted Hamp1/ or either of
the WT groups, had CFU in blood and liver (Figure 3A). For the
WT groups, the iron-dependent difference in CFUs was
observed at a higher inoculum (105 CFU; Figure 3B). These
data indicate that in both Hamp1/ and WT mice, bacterial
replication and dissemination is highly dependent on the host’s
iron status. As shown in Figure 1, mortality from V. vulnificus
infection did not correlate with baseline liver iron concentrations;
therefore, we hypothesized that the difference in baseline serum
iron concentrations, baseline nontransferrin-bound iron (NTBI),
and/or the ability to generate hypoferremia may explain the
disparate susceptibility of Hamp1/ and WT mice and the iron
dependence of bacterial growth in vivo. Indeed, WT mice low-
ered their serum iron concentrations in response to infection
(Figure 3C, mean of 26 mM in iron-depleted and 30 mM in iron-
loaded infected mice), whereas Hamp1/ mice had a much
smaller decrease in serum iron (mean of 63 mM in iron-depleted
and 52 mM in iron-loaded infected mice), insufficient to affect the
replication of V. vulnificus. The slight decrease in Hamp1/
serum iron may be a consequence of decreased food intake, a
common trait in sick mice, or due to direct effects of inflamma-
tory cytokines on ferroportin mRNA (Ludwiczek et al., 2003).
AmongHamp1/mice, despite similar serum iron concentra-
tions in iron-loaded and iron-depleted groups, the iron-loaded
group had higher CFU counts in the blood and liver (Figure 3A).
This difference in bacterial burden may be related to the differ-
ence in the serum concentrations of NTBI, a known source of
iron for V. vulnificus (Kim et al., 2007). NTBI was only detected
in iron-loaded mice (1.28 ± 0.60 LPI units), but not in the iron-
depleted group (Figure 3D), correlating with the bacterial burden.
WT mice had low NTBI levels, similar to those in iron-depleted
Hamp1/ mice, suggesting that NTBI did not contribute to
bacterial growth in WT mice. Among WT mice infected with the
high inoculum (105 CFU), the iron-loaded group had higher
CFU counts in the blood and liver than the iron-depleted group
(Figure 3B), despite the similar degree of hypoferremia 16 hr after
infection (Figure 3C). As NTBI levels were not significantly
different between these two groups, it is likely that serum iron
concentrations during the early stages of infection (prior to the
hepcidin increase and hypoferremia) also contribute to suscep-
tibility to V. vulnificus infection. Thus, our data suggest that
baseline concentrations of transferrin-bound and non-trans-
ferrin-bound iron as well as reactive hypoferremia, all of which
are controlled by hepcidin, determine the replication and
dissemination of V. vulnificus in vivo.
Hepcidin Levels Increase Early after V. vulnificus
Infection
Only WT, but not Hamp1/, animals were able to generate
significant hypoferremia, suggesting that hepcidin mediates
inflammatory hypoferremia during infection. To confirm this
hypothesis, we analyzed hepatic hepcidin mRNA and serum
hepcidin protein at 3, 6, and 10 hr after infection with 105
V. vulnificus in iron-loaded and iron-depleted WT mice. As ex-
pected, iron-loaded mice had higher levels of hepcidin mRNA
and protein compared to iron-depleted mice at all time points
(Figures 4A and 4B). By 6 hr after infection, both iron-depleted
and iron-loaded mice acutely increased their hepatic hepcidinost & Microbe 17, 47–57, January 14, 2015 ª2015 Elsevier Inc. 49
Figure 3. Iron-Dependent Dissemination of
V. vulnificus in Blood and Liver
(A–D) Wild-type and Hamp1/ mice were iron
depleted or iron loaded by dietary modification
(WT: 4 ppm or 10,000 ppm Fe diet for 2 weeks;
Hamp1/: 4 ppm or standard diet for 4–6 weeks;
see Experimental Procedures) and infected with
V. vulnificus (n = 5–10 per group).
(A and B) Bacterial counts in blood and liver 16 hr
after infection with 300 CFU (A) and 105 CFU (B).
Each symbol represents onemouse (iron depleted
in blue and iron loaded in red); black solid lines
represent the mean of CFU counts; black dotted
line represents the lower limit of detection of CFU
counts (calculated as half of the minimum
detectable CFU counts).
(C) Serum iron levels of WT (105 CFU) and
Hamp1/ (300 CFU) mice (white fill = saline
groups; gray fill = V. vulnificus groups). Unlike WT
mice, which decreased their serum iron to the
mean of 30 mM, Hamp1/mice did not develop
marked hypoferremia after infection.
(D) Measurement of non-transferrin-bound iron in
serum of iron-depleted and iron-loaded WT and
Hamp1/ mice prior to infection (n = 4–6 per
group). Statistical significance was assessed
using Student’s t test if data were normally
distributed (*p < 0.05; **p < 0.01; ***p < 0.001) or
Mann-Whitney U test if they were not (+p < 0.05;
++p < 0.01). See also Figure S3.mRNA (Figure 4A) as well as serum hepcidin concentration (Fig-
ure 4B) compared to uninfected mice. At 10 hr after infection,
serum hepcidin increased further in iron-depleted mice and sta-
bilized at very high levels in iron-loaded mice (Figure 4B). These
increases in hepcidin concentrations were accompanied by a
significant decrease in serum iron at 6 hr and 10 hr in iron-
depleted mice (Figure 4C) and a trend toward decreased serum
iron in iron-loaded mice. The latter may not have decreased
serum iron as efficiently because iron-loaded hepatocytes, mac-
rophages, and enterocytes expressmore ferroportin (Chua et al.,
2006; Delaby et al., 2005; Zoller et al., 2002).
IL-6 is thought to be the predominant stimulus for hepcidin
synthesis during inflammation (Nemeth et al., 2004a; Rodriguez
et al., 2014). We found dramatically increased serum concentra-
tions of this proinflammatory cytokine in infectedmice starting at
3 hr after infection (Figure 4D), with no differences between iron-
depleted and iron-loaded mice. A similar increase was also
observed for the inflammatory cytokines KC-GRO, IL-12p70,
IL-1b, TNF-a, IL-10, and IL-2, while IFN-g, IL-4, and IL-5
remained unchanged (Figure S4C). We also observed early
increases in hepatic Saa1 and Inhbb mRNA (Figures S4A
and S4B).
Interestingly, at 16 hr after infection, no statistically significant
differences in hepcidin were observed between infected and
saline-treated WT mice, at either the hepatic mRNA or serum
protein levels (Figures S3A and S3B), despite increased inflam-
matory markers, including hepatic Saa1 mRNA (Figure S3C)
and proinflammatory cytokines in the serum (Figure S3E). Inhbb
mRNA, coding for the bB subunit of activin B, a protein involved in50 Cell Host & Microbe 17, 47–57, January 14, 2015 ª2015 Elsevier Ian alternative pathway for hepcidin regulation by inflammation,
was also increased in infected iron-loaded groups (Figure S3D).
These data imply that hepcidin production in the liver was rapidly
increased early in the course of infection by inflammatory medi-
ators induced by bacterial infection. Elevated hepcidin in turn
caused acute hypoferremia. The hypoferremia appears to coun-
terregulate hepcidin so that by 16 hr, hepcidin levels in infected
WT mice were no longer different from those of uninfected
controls.
Minihepcidin PR73 Protects against Mortality from
Infections with Vibrio vulnificus
To further examine the importance of early hepcidin activity for
resistance to V. vulnificus infection, we tested the therapeutic ef-
fect of minihepcidin PR73 (a synthetic hepcidin agonist; Fig-
ure S5) in Hamp1/ mice. We used minihepcidin because it
has greater potency and a longer-lasting effect than full-length
hepcidin (Ramos et al., 2012). Mice were pretreated with PR73
24 hr and 3 hr before infection and were euthanized 16 hr after
s.c. infection with 300CFU of V. vulnificus. Administration ofmin-
ihepcidin caused marked hypoferremia (3 mM in iron-depleted
and 9 mM in iron-loaded mice) (Figure 5A). Liver iron stores did
not change, likely because of the short duration of the experi-
ment (40 hr) (Figure 5B). Importantly, minihepcidin treatment re-
sulted in decreased numbers of bacteria in blood and liver of
both iron-depleted and iron-loaded mice (Figures 5C and 5D).
Pretreatment with PR73 also markedly improved survival: while
most of the nontreated Hamp1/ mice died within 2 days after
infection with 103 or 105 CFU of V. vulnificus, mice treated withnc.
Figure 4. WT Mice Respond to V. vulnificus
Infection by Rapidly Increasing Plasma
Hepcidin Concentration
(A–D) WT mice, either iron depleted (blue) or iron
loaded (red), were injected with 105 CFU
V. vulnificus (solid lines) or saline (dashed lines)
and euthanized after 3, 6, or 10 hr. (A) Hepatic
Hamp1 mRNA expression. (B) Serum hepcidin
concentration. (C) Serum iron concentration. (D)
The inflammatory response to infection was
confirmed by serum IL-6 assay. Each point rep-
resents the mean ± SD (n = 5). Statistical signifi-
cance was assessed using Student’s t test if data
were normally distributed (*p < 0.05; **p < 0.01;
***p < 0.001) or Mann-Whitney U test if they were
not (+p < 0.05; ++p < 0.01). See also Figure S4.minihepcidin survived, regardless of their iron load and regard-
less of the number of bacteria administered (Figures 6A and 6B).
To test whether minihepcidins are effective for not only the
prevention, but also postexposure treatment, of V. vulnificus
infection, we injected PR73 in iron-loaded Hamp1/ mice 3 hr
after infection with 103 CFU of bacteria. Even delayed injection
(postexposure treatment) of PR73 significantly increased the
survival of these highly susceptible mice (Figure 6C).
To determine if the anti-Vibrio effect of minihepcidin was due
to iron restriction of bacterial growth or a direct bactericidal ef-
fect of the PR73 peptide, we measured the growth and killing
of a V. vulnificus strain marked by a chloramphenicol-resistance
plasmid, similarly to a published approach (Figure S7) (Gulig
et al., 1997). The marker plasmid only replicates in the presence
of arabinose, which is not present in significant amounts in
mouse serum. Bacteria were grown ex vivo in sera that were ob-
tained from Hamp1/ mice treated with PR73 minihepcidin or
with a solvent control. Iron concentrations of these sera are pro-
vided in Table S2. After incubating bacteria in the mouse sera for
2 hr, CFU counts were determined on plates that allow only
plasmid-containing bacteria to grow (supplemented with chlor-
amphenicol and arabinose) or plates that allow all Vibrio bacteriaCell Host & Microbe 17, 47–5to grow (no chloramphenicol/arabinose).
Because the marker plasmid does not
replicate in bacteria growing in serum,
the reduction in CFU of plasmid-contain-
ing Vibrio reflects the killing of the
inoculum. The number of total Vibrio
CFU reflects both growth and killing of
bacteria, whereas the ratio of total
to plasmid-containing bacteria (T/P) re-
flects growth only (Gulig et al., 1997)
(Figure S7).
After incubation in ex vivo sera, total
CFU were 15- to 20-fold lower in sera
of minihepcidin-treated Hamp1/ mice
compared to the sera of solvent-treated
Hamp1/ mice (Figure 7A), regardless
of whether the donor mice were on
low- or high-iron diet, mirroring the
in vivo CFU results (Figures 5C and
5D). In contrast, CFU of the plasmid-containing bacteria were merely 1.7- to 1.9-fold lower in mini-
hepcidin-treated sera relative to the solvent sera (Figure 7B),
demonstrating that the peptide had only a slight bactericidal
effect in serum. T/P ratios (i.e., bacterial growth) were about
10-fold lower for sera from the minihepcidin-treated mice
compared with the solvent controls (Table S2), indicating that
minihepcidin-triggered hypoferremia significantly decreased
bacterial replication. This effect of hypoferremia on Vibrio
growth was also replicated using sera from noninfected WT
mice that were fed low- or high-iron diet (Figures 7C and
7D). Moderately hypoferremic sera (because of low-iron diet)
slowed down Vibrio growth compared to iron-rich sera
(because of high-iron diet), as shown by a T/P ratio decreased
by greater than 10-fold (Table S2), without affecting the num-
ber of plasmid-containing bacteria (Figure 7D). Thus, minihep-
cidin-induced hypoferremia, rather than a direct antimicrobial
effect of minihepcidin, was responsible for slower Vibrio
replication.
Like healthy humans, WT mice, which appropriately respond
to infection by inducing endogenous hepcidin, are highly resis-
tant to V. vulnificus infection. When very large inocula of
V. vulnificus (106 and 107 CFU) were administered to WT mice,7, January 14, 2015 ª2015 Elsevier Inc. 51
Figure 5. Minihepcidin PR73 Decreases Infection by V. vulnificus in
Hamp1–/– Mice
(A–D) Hamp1/ mice (either iron depleted or iron loaded) were treated with
100 nmol of PR73 (red symbols) or solvent (white symbols) 24 hr and 3 hr
before infection with 300 CFU V. vulnificus. Mice were euthanized 16 hr after
infection. n = 10–11 per group.
(A) Serum iron was markedly decreased in PR73-injected mice, with no dif-
ference in serum iron between solvent-injected iron-depleted and iron-loaded
mice.
(B) Liver iron was higher in iron-loaded than in iron-depleted mice, as ex-
pected. PR73 administration did not result in significant changes in liver iron
stores.
(C) In iron-depleted Hamp1-/ mice (C) and iron-loaded Hamp1-/ mice (D),
V. vulnificus was undetectable in blood and liver in PR73-treated mice, in
contrast to mice treated with saline. Each dot represents one mouse; black
solid lines represent the mean of CFU counts. The black dotted line represents
the lower limit of detection of CFU counts (calculated as half of the minimum
detectable CFU counts). Statistical significance was assessed using Student’s
t test if data were normally distributed (**p < 0.01) or Mann-Whitney U test if
they were not (+p < 0.05; ++p < 0.01). See also Figure S5.minihepcidins did not further protect them from lethal infection
(Figure S6), arguing against a direct microbicidal effect of these
peptides in vivo.
DISCUSSION
The growth of pathogens in their hosts is critically dependent on
the pathogens’ ability to capture and utilize iron. The hosts have
evolved several countermeasures to restrict the bioavailability of
iron and effectively starve the microbes (Ganz, 2009). Hepcidin-
induced hypoferremia has been proposed as an important host
defense mechanism (Drakesmith and Prentice, 2012; Ganz,
2009), but specific support for its role has been lacking. In this
study, we show that acute hypoferremia is an important host de-
fense mechanism against the siderophilic bacterial pathogen
V. vulnificus.52 Cell Host & Microbe 17, 47–57, January 14, 2015 ª2015 Elsevier IAfter infection with V. vulnificus, iron-loaded mice had greater
bacterial CFU burden in blood and the liver. Moreover, ex vivo
sera that had excess iron promoted the rapid growth of
V. vulnificus. This is not a result of the inability of these bacteria
to utilize iron at its physiologic concentration because bacteria
grew well even in sera with relatively low iron levels. Rather,
high iron levels trigger extraordinarily rapid V. vulnificus growth,
with bacteria dividing every 10 min. We speculate that high
iron concentrations, or possibly the related presence of one or
more non-transferrin-bound iron (NTBI) forms in the environment
of V. vulnificus, activate a genetic program for very rapid growth,
leading to septicemia, high cytokine concentrations, evidence of
septic shock at necropsy, and early mortality. The early mortality
of susceptible humans after infection with these bacteria sug-
gests that a similar program may be activated during human in-
fections with V. vulnificus.
In our mouse models, the order of susceptibility to rapid
mortality from V. vulnificus was Hamp1/ iron loaded >
Hamp1/ iron depleted > WT iron loaded > WT iron depleted.
This, together with studies of the effect of serum iron on
V. vulnificus growth ex vivo, indicated that plasma iron concen-
trations during the course of infection determined the growth
of V. vulnificus and host mortality. Hamp1/ mice were more
susceptible to lethal infection, even when they had the same
baseline serum iron and lower liver iron stores than iron-loaded
WT mice. This suggests that acute hypoferremia after infection
is a major iron-related determinant of resistance to V. vulnificus.
WT mice developed hypoferremia within hours after infection
with V. vulnificus, and this response was dependent on early in-
duction of hepcidin, preceded by a rise in inflammatory cyto-
kines such as IL-6 and activin B. IL-6 acts as an inflammatory
signal that triggers hepcidin expression in the liver through the
JAK/STAT3 pathway (Nemeth et al., 2004a; Verga Falzacappa
et al., 2007; Wrighting and Andrews, 2006). Activin B, through
SMAD1/5/8 signaling (Besson-Fournier et al., 2012), is also a
stimulus for hepcidin production in response to inflammation.
We found that expression of Inhbb, encoding the activin bB sub-
unit, is increased prior to the hepcidin response, suggesting that
the two pathways may cooperate in the induction of hepcidin
during infection.
To further examine if hepcidin-induced hypoferremia is an
effective component in the innate immune response against
V. vulnificus, we analyzed the therapeutic effects of minihepci-
dins in Hamp1/ mice. Minihepcidins are synthetic hepcidin
agonists previously shown to bind ferroportin and induce its
endocytosis and proteolysis, thus preventing iron overload in
hepcidin-deficient mice (Preza et al., 2011; Ramos et al.,
2012). In the current study, the short-term minihepcidin treat-
ment robustly decreased serum iron without altering liver iron
stores. Both pretreatment with minihepcidin and administra-
tion 3 hr after the infection protected the highly susceptible
Hamp1/ mice from dying from infection, even with a large
inoculum of V. vulnificus. Minihepcidin-treated mice had
much lower concentrations of bacterial CFU in the blood and
liver, presumably because of a lower bacterial growth rate
due to decreased plasma iron. WT mice with their intact
endogenous hepcidin response to infection were not further
protected by minihepcidins injections. This limitation is not
clinically important because healthy humans do not developnc.
Figure 6. Minihepcidin PR73 Prevents Death Due to V. vulnificus
Infection in Hamp1–/– Mice
(A–C) Kaplan-Meier survival curves (n = 4–5 per group). Both iron-depleted (A)
and iron-loaded (B) Hamp1/ mice survived the infection with 103 and 105
CFU V. vulnificus when treated with 100 nmol PR73 (red) before the infection.
(C) Hamp1/mice were resistant to infection, even if PR73 was administered
3 hr after infection. Statistically significant differences in survival between
solvent- and PR73-treated mice were assessed using the log-rank survival
analyses: p < 0.05 for iron depleted, 103 CFU; p < 0.01 for the other groups.
See also Figure S6.severe V. vulnificus infections. Another study (Pan et al., 2012)
showed that treatment with tilapia hepcidin TH(2-3) did in-
crease survival rate in Balb/C mice infected with V. vulnificus
and that TH(2-3) had both antimicrobial and immunomodula-
tory effects. However, effects on iron metabolism were not
investigated, and it is not known if TH(2-3) interacts with
murine ferroportin.
Since hepcidin and its fragments have microbicidal effects
in vitro (Park et al., 2001), we tested if the minihepcidin had a
bactericidal effect on V. vulnificus. By using a V. vulnificus strain
containing a marker plasmid, pGTR905, that functions as a
replicon only in the presence of arabinose (a sugar not found in
relevant concentrations in animal tissues), we demonstrated
that the minihepcidin-containing serum had only a slight bacte-
ricidal effect that was not sufficient to explain the dramatically
lower number of total bacterial CFU. Rather, the slower growth
of bacteria in sera from minihepcidin-treated mice was caused
by the low iron concentrations in those sera. The dependence
of V. vulnificus growth in ex vivo sera on the serum iron concen-
trations was confirmed in WT mice, where serum iron was
manipulated not by the administration of minihepcidin, but by
changing the dietary iron content. The composition of sera is
also not favorable for the direct microbicidal activity of hepcidin,Cell Hwhich is dependent on acidic pH that is not physiologic in serum
(Maisetta et al., 2010).
We cannot exclude the possibility that immunological differ-
ences exist between Hamp1/ and WT mice, even when
Hamp1/mice are kept on a low-iron diet. Hepcidin deficiency
results in altered tissue iron distribution and iron-depleted mac-
rophages, and this could potentially affect innate immune
signaling (Oexle et al., 2003; Wang et al., 2009). However, the
ability of minihepcidins to rapidly alleviate the mortality of
Hamp1/ mice from V. vulnificus infection would argue that
any immunological differences between Hamp1/ and WT
mice are minor or acutely reversible by hepcidin or its analogs.
A recent study showed that genes encoding proteins involved
in V. vulnificus iron acquisition (siderophore receptor vuuA and
components of siderophore synthase) were induced in bacteria
collected from infected patients (Bisharat et al., 2013). Deletion
of the vuuA gene, which impaired iron uptake from both trans-
ferrin and siderophore vulnibactin, resulted in reduced virulence
inmice (Webster and Litwin, 2000). However, despite the evident
link between the iron uptake and virulence of V. vulnificus,
the molecular mechanism by which excess iron reprograms
V. vulnificus for very rapid growth is still elusive.
Human hereditary hemochromatosis is a well-established risk
factor for lethal infection with V. vulnificus. However, the severity
of hepcidin deficiency and iron overload in humans is highly var-
iable, particularly in the most common form caused by the
C282Y HFE mutations (Waalen et al., 2002). The variability is
attributable to both genetic modifiers (e.g., gender) and environ-
mental factors (e.g., alcohol intake). Therefore, patients with mild
or normal phenotypes will likely not be at increased risk of side-
rophilic infections. Indeed, studies in HFE knockout mice
showed appropriate decrease in serum iron in response to LPS
(Wallace et al., 2011). Only when a second hemochromatosis
gene TfR2 is ablated is the hypoferremic response to LPS lost
(Wallace et al., 2011). Like the HFEmouse model, in the absence
of additional genetic or comorbid factors, most patients with
HFE mutations may appropriately respond to infections by
increasing hepcidin and developing hypoferremia. In contrast,
the loss of hepcidin in Hamp1/ mice generates a particularly
severe form of the disease, and it nearly completely ablates
the hypoferremia of infection. We hypothesize that those hemo-
chromatosis patients with very low baseline hepcidin and
impaired hepcidin response to infection, either because of the
pattern of causative mutations and/or the presence of comorbid
factors, will have increased susceptibility to infections with side-
rophilic bacteria.
Hepcidin deficiency in humans, such as in fully penetrant
forms of hereditary hemochromatosis, is associated with the
appearance of NTBI in plasma (Brissot et al., 2012). NTBI was
shown to promote the growth of V. vulnificus in cirrhotic ascites
(Kim et al., 2007) even better than holotransferrin. Our results
also demonstrate that the growth ofV. vulnificus in vivowas high-
ly enhanced in sera containing NTBI. One effect of therapeuti-
cally induced hypoferremia in iron overload would be the loss
of NTBI from blood plasma. Further studies are required to eluci-
date the requirement of NTBI for Vibrio growth in serum and
in vivo and its potential mechanisms.
In summary, hepcidin plays an important role in host defense
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Figure 7. Minihepcidin PR73 Acts in Serum
by Slowing Bacterial Growth
(A–D) Serum was collected from iron-depleted or
iron-loaded Hamp1/ mice that were injected
with PR73 or solvent and from iron-depleted or
iron-loaded WT mice (not treated with PR73).
Serum iron concentrations are shown in Table S2.
V. vulnificus carrying the nonreplicating marker
plasmid pGTR905 was incubated in these sera
in vitro for 2 hr, andCFUwere determined on either
plates without chloramphenicol (total bacteria) or
plates with chloramphenicol and arabinose (allows
growth of only plasmid-containing bacteria).
(A) PR73 greatly reduced total bacterial yield,
which reflects the sum of bacteriostatic and
bactericidal effects.
(B) PR73 only slightly reduced the yield of plasmid-
containing bacteria, indicating only a small
bactericidal effect.
(C) The number of total bacteria was much higher
in serum from iron-loaded WT mice than in serum
from iron-depleted mice, as expected.
(D) Different serum iron concentrations did not
affect the yield of plasmid-containing bacteria,
indicating that hypoferremia by itself does not
have a bactericidal effect.
Each vertical bar represents the mean, and error
bars represent SD for three independent experiments (with 3 replicates in each experiment). The black dotted line represents the number of plasmid-containing
bacteria after growth that diluted plasmid copy number to 1 plasmid per bacterium (thus bacteria in the original inoculum carried 5 plasmids per bacterium).
Statistical significance was assessed using Student’s t test (*p < 0.05; **p < 0.01; ***p < 0.001). See also Figure S7.baseline plasma iron concentrations and mediating hypoferre-
mia in response to infection. These effects prevent the rapid
growth of V. vulnificus so that other innate immune mechanisms
are sufficient to control the infection. Pointing to potential
therapeutic applications, pre- or postinfection administration of
hepcidin agonists to hepcidin-deficient mice increased their
resistance to V. vulnificus infection and protected them from
consequent mortality.
EXPERIMENTAL PROCEDURES
Preparation of Bacteria
Vibrio vulnificus CMCP6 strain was grown in Luria-Bertani broth (Becton Dick-
inson) containing 0.85% NaCl (LB-N), and bacterial stocks were stored at
80C in LB-N with 35% glycerol. The day before the experiment, 50 ml of
V. vulnificuswas diluted 1:1,000 in LB-N and grown at room temperature over-
night. On the day of infection, the culture was diluted 1:30 in LB-N and shaken
at 37C until the optical density at 600 nm reached 0.3. Bacteria were then har-
vested by centrifugation (138003 g for 10 min at 4C) and suspended in 0.9%
sodium chloride injection solution (Hospira) at the required concentrations.
Bacterial CFU were counted by plating 6 ml of serial dilutions of blood, ho-
mogenized liver, or bacterial suspension on LB-N plates containing 1.5%
agar and enumerating the bacterial colonies after incubation at 37C.
Animal Studies
All experiments involving animals were approved by the University of Califor-
nia, Los Angeles (UCLA) Office of Animal Research Oversight. C57BL/6 wild-
type mice were obtained from Charles River Laboratories. Hepcidin-1
knockout (Hamp1/) mice, originally provided by Dr. Sophie Vaulont (Les-
bordes-Brion et al., 2006) and backcrossed by us onto the C57BL/6 back-
ground using marker-assisted accelerated backcrossing (Ramos et al.,
2012), were bred in our vivaria. Only male mice were used. WT and Hamp1/
mice were iron depleted or iron loaded using dietary manipulations. Starting at
6 weeks of age, WT mice were fed an iron-poor (4 ppm Fe) or iron-rich (10,000
ppm Fe) diet (Harlan) for 2 weeks. Starting at 4–5 weeks of age, Hamp1/54 Cell Host & Microbe 17, 47–57, January 14, 2015 ª2015 Elsevier Imice were fed an iron-poor (4 ppm Fe) or standard diet (270 ppm Fe) for 4–
6 weeks before the infection. The earlier start and longer regime of low-iron
diet inHamp1/was necessary to achieve substantial iron depletion because
these mice are already iron overloaded at a young age.
For survival experiments, animals were infected by s.c. injection (100 ml)
in the interscapular area with 103–107 CFU of V. vulnificus suspended in
0.9% sodium chloride (Hospira). Control mice received equivalent injections
of saline only. Mice were observed for 4 days or euthanized earlier by isofluor-
ane (Clipper) inhalation if they became moribund.
For tissue and blood collection, WT and Hamp1/ were infected with
300 CFU (and 105 only in WT mice), and control animals received saline-only
injections. Mice were euthanized 16–18 hr after infection, were exsanguinated,
and their livers were harvested. For histhopathology analysis, Hamp1/mice
were injected with 103 CFU of V. vulnificus or saline and euthanized 10–12 hr
after infection, and a piece of the liver and the injection site (skin) were
collected into tubes containing 4% formalin.
To analyze early changes in iron, hepcidin, and proinflammatory cytokines
after infection, WT mice (fed an iron-poor or iron-rich diet for 2 weeks) were in-
jected with 105 CFU of V. vulnificus or saline, and animals were euthanized at 3,
6, or 10 hr after infection.
To test the therapeutic effects of minihepcidin, mice were injected intraper-
itoneally with 100 nmol of minihepcidin PR73 dissolved in 100 ml of SL220
(Preza et al., 2011; Ramos et al., 2012) (a PEG-phospholipid based solubilizer,
NOF Corporation), whereas control groups were injected with the same
amount of solvent. For minihepcidin pretreatment studies, animals were in-
jected 24 hr and 3 hr before infection. For treatment studies, animals received
minihepcidin or solvent injection 3 hr after the infection. In both experiments,
surviving animals also received minihepcidin or solvent injection 24 and
48 hr after infection.
Peptide Synthesis
Minihepcidin PR73 was synthesized as a C-terminal amide using standard
solid-phase Fmoc chemistry and was purified by preparative reverse-phase
high-performance liquid chromatography (RP-HPLC). Its purity was evaluated
by MALDI-MS as well as analytical RP-HPLC. From N to C terminus, the
primary sequence of PR73 was as follows: iminodiacetic acid, L-threonine,nc.
L-histidine, L-3,3-diphenylalanine, L-b-homoproline, L-arginine, L-cysteine, L-
arginine, L-b-homophenylalanine, 6-aminohexanoic acid, iminodiacetic acid
palmitylamide (Ida-Thr-His-Dpa-bhPro-Arg-Cys-Arg-bhPhe-Ahx-Ida(NHPal)-
CONH2).
Serum and Liver Iron Measurements
Blood was collected in serum separator tubes (BD) and allowed to clot at room
temperature for 30 min followed by centrifugation for 5 min, 4,500 rpm at 4C.
The serumwas transferred to new tubes for serum iron quantification using the
colorimetric Iron-SL assay (Sekisui Diagnostics) following the manufacturer’s
instructions. For liver iron measurements, the tissue was homogenized, and
a 75 ml sample was added to 1,125 ml of protein precipitation solution
(0.53M HCl and 5.3% trichloroacetic acid; Fisher Scientific). The samples
were heated at 100C for 1 hr and centrifuged for 10 min (13,000 rpm at
4C), and the supernatant was used for the Iron-SL assay, measuring the
absorbance at 595 nm relative to Iron AA Standard (Ricca Chemical Com-
pany). Results are expressed as mg Fe per gram of wet liver weight.
Histopathology Analysis
Liver and skin sections were fixed in 4% formalin for 12 hr, imbedded in
paraffin, cut in 5-micron sections, and stained with hematoxylin and eosin at
the UCLA Translational Pathology Core Laboratory. Skin sections were also
stained using the Gram Stain for Tissue kit (Sigma) following the manufac-
turer’s instructions. Microscopic images were acquired on a Nikon Eclipse
E600 microscope using Nikon Plan Fluor 43/0.13, Plan Apo 103/0.45, Plan
Apo 403/0.95, and Plan Fluor 1003/1.30 objectives with a Spot RT3 2MP
Slider camera and Spot 5.0 software. Pictures were assembled using Adobe
Photoshop CS5.
Labile Plasma Iron Quantification
Labile plasma iron (LPI), a redox-active form of non-transferrin-bound iron
(Esposito et al., 2003), was measured using the FeROS eLPI kit (aFerrix) ac-
cording to the manufacturer’s instructions. Briefly, 20 ml of mouse serum
was plated in duplicate in 96-well plates. Serum was treated with 100 ml of
LPI reagent containing buffered 2,3-dihydrorhodamine and ascorbate in the
presence or absence of an iron chelator. Fluorescence resulting from oxidation
of 2,3-dihydrorhodamine after exposure to reactive oxygen species was
measured in a Gemini XS microplate reader (Molecular Devices) using
495 nm for excitation and 525 for emission. A kinetic measurement was per-
formed every 2 min for 40 min. The DFU/min for each sample, with or without
the iron chelator, was converted to LPI units by comparing it with the standard
values obtained in the same test. Values higher than 0.2 were considered
indicative for the presence of NTBI.
Gene Expression Analysis
RNA from mouse liver was extracted by TRIzol Reagent (Life Technologies),
and cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad)
following manufacturer’s instructions. Real-time quantification of transcripts
was performed in duplicates in a CFX96 Touch Real-Time PCR Detection
System (Bio-Rad) using Sso Advance SYBR Green Supermix (Bio-Rad) and
specific primers for Hamp1 (forward: TTGCGATACCAATGCAGAAGA;
reverse: GATGTGGCTCTAGGCTATGTT), Inhbb (forward: CTCCGAGATCAT
CAGCTTTGC; reverse: GGAGCAGTTTCAGGTACAGCC), Saa1 (forward:
AGTCTGGGCTGCTGAGAAAA; reverse: ATGTCTGTTGGCTTCCTGTG), and
Actb (forward: ACCCACACTGTGCCCATCTA; reverse: CACGCTCGGTCAG
GATCTTC). Data were normalized to the expression of b-actin.
Serum Hepcidin Assay
Mouse hepcidin ELISA was performed as previously described (Kim et al.,
2014). Mouse hepcidin-1 monoclonal antibodies, Ab2B10 (capture) and
AB2H4-HRP (detection), as well as synthetic mouse hepcidin-25, were a
generous gift from Amgen. High-binding 96-well EIA plates (Corning Costar)
were coated overnight at room temperature with 50 ml/well of 3.6 mg/ml
Ab2B10 in 0.2M carbonate-bicarbonate buffer (pH 9.4) (Pierce, Thermo Scien-
tific). Plates were washed two times with wash buffer (PBS, 0.5% Tween-20)
and then blocked for 45 min with 200 ml/well-blocking buffer (PBS, 1% BSA,
1% goat serum, 0.5% Tween-20). Serum samples (previously diluted in block-
ing buffer at 1:10,000 for iron-loaded mice or 1:1,000 for iron-depleted mice)Cell Hand standards were incubated for 1 hr at room temperature (50 ml/well),
washed four times with wash buffer, incubated for 1 hr with 50 ml/well
of 130 ng/ml Ab2H4-HRP, washed four times, and then developed with
100 ml/well Ultra-TMB substrate (Thermo Scientific) for 15 min in the dark at
room temperature. The reaction was stopped by adding 50 ml 2 M sulfuric
acid, and the absorbance was measured at 450 nm using a 96-well plate
reader (Molecular Devices).
Analysis of the Bactericidal and Bacteriostatic Effects of
Minihepcidin on V. vulnificus
To analyze the mode of action of minihepcidin PR73, we used V. vulnificus
CMCP6 containing pGTR905, a marker plasmid that confers resistance to
chloramphenicol, as described in Starks et al. (2006). The plasmid replicates
only in the presence of arabinose, which is not found in mouse tissues.
Thus, the loss of plasmid from the bacterial population during growth in mouse
serum is a measure of bactericidal activity. The principle is graphically illus-
trated in Figure S7.
The plasmid-containing bacterial inoculum was first grown in LB-NAC,
LB-N broth supplemented with 1% L-arabinose (Sigma) and 5 mg/ml chlor-
amphenicol (Sigma), to enable and select for plasmid replication. The bac-
teria were then washed and suspended in LB-N at 105 CFU/ml, and 10 ml
were added to 40 ml of mouse serum in 96-well plates. Serial 5-fold dilutions
were performed in serum. Serum samples were obtained from Hamp1/
mice kept on an iron-poor or standard diet for 4–6 weeks and injected
24 hr and 3 hr before blood collection with 100 nmol PR73 in SL220 or
with SL220 only (five mice per group). Sera were also collected from WT
mice kept on iron-poor or iron-rich diet for 2 weeks (five mice per group).
For each mouse group, sera was pooled and used for in vitro experiments.
96-well plates with bacteria were incubated for 2 hr at 37C with shaking
(300 rpm), using triplicates for each condition. 5 ml from each well was
plated on LB-N and LB-NAC plates (containing 1.5% agar), and CFU
were counted for each plate.
Quantification of Inflammatory Cytokines in Serum
Inflammatory cytokines (IFN-g, IL-1b, IL-2, IL-4, IL-5, IL-6, KC/GRO, IL-10,
IL-12p70, and TNF-a) were measured in mouse serum using the Proinflam-
matory Panel 1 (mouse) kit (Meso Scale Discovery) following manufac-
turer’s instructions. Briefly, 50 ml of standards and 2-fold diluted samples
were added to a 10-spot multiplex plate precoated with capture antibodies,
and the plate was incubated at room temperature with shaking for 2 hr. Af-
ter washing three times with wash buffer (PBS supplemented with 0.05%
Tween-20), 25 ml of detection antibody was added to each well and incu-
bated for 2 hr, washed three times, and incubated with 150 ml of 2X read
buffer (provided with the kit). The plate was read in a chemiluminescence
reader (SECTOR Imager 2400, Meso Scale Discovery), and data were
analyzed using the MSD Discovery workbench software (Meso Scale
Discovery).
Statistical Analysis
The statistical significance of differences between groupswas evaluated using
Student’s t test if data were normally distributed or Mann-Whitney U test if this
condition was not met. Survival differences were analyzed using Kaplan-Meier
survival curves and log-rank test. All statistics were done using Sigmaplot 12.5
(Systat Software).
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